CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.
Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, Vicente-García F, Blanco-Luquin I, De La Cruz S, Aramendia A, Guerrero-Setas D. Clin Epigenetics. 2017; 9:7. Epub 2017 Jan 24.